{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-003149","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.874008+00:00","generated_at":"2026-06-27T20:15:57.670423+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer","bullets":["NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.","Margetuximab is the only HER2-targeted agent to show PFS improvement vs trastuzumab in head-to-head Phase 3 SOPHIA trial.","NDA acceptance marks Zai Lab's sixth NDA acceptance by NMPA and expands women's oncology franchise.","Bridging study in Chinese patients met primary endpoint of PFS by BICR; safety consistent with SOPHIA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-003149","json":"https://secwatch.observer/filing/0001193125-22-003149.json","markdown":"https://secwatch.observer/filing/0001193125-22-003149.md","text":"https://secwatch.observer/filing/0001193125-22-003149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/0001193125-22-003149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/d274826d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:15:57.670423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}